Zonisamide-13C2,15N Biochemical

Zonisamide-13C2,15N

Cat. Num. AAA227348

• Purity: 98%
• Synonyms: Zonisamide-13C2,15N; N/A; Zonisamide-13C2,15N biochemical

• Purity/Purification: 98%

• SMILES: [15NH2]S([13CH2][13C]1=NOC2=CC=CC=C21=O)=O
• Formula: C6[13C]2H8N[15N]O3S
• CAS: 1188265-58-8
• Solubility: Methanol: Slightly soluble; ; DMSO: Slightly soluble; <1mg/ml refers to the product slightly soluble or insoluble
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(Atenolol Hydrochloride, CAS 51706-40-2)

Structure

(Atenolol Hydrochloride, CAS 51706-40-2)

Related Product Information for Zonisamide-13C2,15N biochemical

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 ug/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 ug/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 uM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and 500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine, but not homovanillic acid or dihydroxyphenyl acetic acid, and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

References

ef="javascript:void(0)" rel="nofollow" >
1. Prachi S, Komal C, Priti MJ. Influence of Peroxide Impurities in Povidone on the Stability of Selected beta-Blockers with the Help of HPLC. AAPS PharmSciTech. 2017 Oct;18(7):2410-2417. doi: 10.1208/s12249-017-0716-2. Epub 2017 Feb 2. PubMed PMID: 28155135. href="javascript:void(0)" rel="nofollow" >
2. Sipos B, Pintye-Hódi K, Kónya Z, Kelemen A, Regdon G Jr, Sovány T. Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems. Int J Pharm. 2017 Feb 25;518(1-2):119-129. doi: 10.1016/j.ijpharm.2016.12.053. Epub 2016 Dec 24. PubMed PMID: 28027919. href="javascript:void(0)" rel="nofollow" >
3. Rimoldi L, Meroni D, Falletta E, Pifferi V, Falciola L, Cappelletti G, Ardizzone S. Emerging pollutant mixture mineralization by TiO(2) photocatalysts. The role of the water medium. Photochem Photobiol Sci. 2017 Jan 18;16(1):60-66. doi: 10.1039/c6pp00214e. PubMed PMID: 27841891. href="javascript:void(0)" rel="nofollow" >
4. Akinyemi AJ, Thomé GR, Morsch VM, Bottari NB, Baldissarelli J, de Oliveira LS, Goularte JF, Belló-Klein A, Oboh G, Schetinger MR. Dietary Supplementation of Ginger and Turmeric Rhizomes Modulates Platelets Ectonucleotidase and Adenosine Deaminase Activities in Normotensive and Hypertensive Rats. Phytother Res. 2016 Jul;30(7):1156-63. doi: 10.1002/ptr.5621. Epub 2016 May 6. PubMed PMID: 27151061.